Semaglutide vs Tirzepatide: Which Weight Loss Peptide Is Right for You?

Two Peptides, One Goal: Fat Loss

Semaglutide and tirzepatide are the most talked-about weight management peptides in 2025–2026. Both are GLP-1 based, but they work differently. Here is a straightforward comparison.

Semaglutide (Ozempic / Wegovy)

• GLP-1 receptor agonist — reduces appetite and slows gastric emptying
• Typical starting dose: 0.25 mg/week, titrating up to 1–2.4 mg/week
• Clinical trials show 10–15% body weight reduction over 68 weeks
• Common side effects: nausea, constipation, fatigue (usually temporary)

Tirzepatide (Mounjaro / Zepbound)

• Dual GLP-1 and GIP receptor agonist — stronger metabolic effect
• Starting dose: 2.5 mg/week, titrating to 5–15 mg/week
• Studies show up to 20–22% body weight loss in some trials
• May cause stronger GI side effects during dose escalation

Semaglutide vs Tirzepatide: Quick Comparison

Choose semaglutide if: you want a well-studied option with a long track record and moderate weight loss goals.

Choose tirzepatide if: you need stronger appetite suppression and are comfortable with a newer dual-action compound.

Where to Buy in Australia

OZ Performance Labs stocks both compounds. Browse Ozempic/Semaglutide and Peptides for current availability and pricing.

These are prescription medications. Consult your doctor before use.

Shop GLP-1 peptides: Semaglutide 5mg | Retatrutide | Wegovy | Ozempic range